Pharmaceutical Transparency and Accountability

This chapter critiques a letter from the CEO of the Association of the British Pharmaceutical Industries, addressing the industry's transparency and the ongoing skepticism towards pharmaceutical practices. It highlights the troubling parallels between pharmaceutical responses to criticism and the tactics of quacks, detailing systemic issues related to clinical trial reporting and the implications of the FDA Amendment Act of 2007.